review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Anna Alisi | Q42430617 |
Valerio Nobili | Q56507694 | ||
Sara Ceccarelli | Q58423082 | ||
P2093 | author name string | Evelina Moraru | |
Otilia E Frasinariu | |||
P433 | issue | 7 | |
P921 | main subject | liver disease | Q929737 |
metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
fatty liver disease | Q6058862 | ||
P304 | page(s) | 543-551 | |
P577 | publication date | 2012-12-29 | |
P1433 | published in | Digestive and Liver Disease | Q15766194 |
P1476 | title | Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies | |
P478 | volume | 45 |
Q47965667 | Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver |
Q38937960 | Beverage consumption and paediatric NAFLD. |
Q55070198 | Crosstalk between the microbiome and epigenome: messages from bugs. |
Q37149656 | Developmental programming of pediatric nonalcoholic fatty liver disease: redefining the"first hit". |
Q51017336 | Endotoxin exposure and puberty in female rats: the role of nitric oxide and caspase-1 inhibition in neonates. |
Q37636566 | Fatty liver in childhood |
Q57295702 | Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics |
Q35147488 | Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. |
Q30887448 | Hepatic hemangioma in celiac patients: data from a large consecutive series |
Q93016049 | Herbal drug discovery for the treatment of nonalcoholic fatty liver disease |
Q28068832 | Implication of the intestinal microbiome in complications of cirrhosis |
Q36062584 | Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation |
Q39301952 | Long-term challenges and perspectives of pre-adolescent liver disease |
Q35084719 | Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications |
Q26769611 | Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies? |
Q52877979 | Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). |
Q38397177 | Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies |
Q48099354 | Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. |
Q36255920 | Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver |
Q47805260 | PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells |
Q92738115 | Paediatricians play a key role in preventing early harmful events that could permanently influence the development of the gut microbiota in childhood |
Q37592952 | Pediatric non-alcoholic fatty liver disease: an increasing public health issue. |
Q57803934 | Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease |
Q33714116 | Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis |
Q36600936 | Subclinical-Dose Endotoxin Sustains Low-Grade Inflammation and Exacerbates Steatohepatitis in High-Fat Diet-Fed Mice |
Q51089692 | Systematic Review of the Relation Between Intestinal Microbiota and Toll-Like Receptors in the Metabolic Syndrome: What Do We Know So Far? |
Q26780509 | The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease |
Q39099711 | The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. |
Q93350798 | The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis |
Q41158897 | Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. |
Search more.